Reslizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Reslizumab. Educational only — not medical advice.
Labeled uses
CINQAIR® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies (14 )] . Limitation of Use: CINQAIR is not indicated for treatment of other eosinophilic conditions. CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2 )] .
Source: FDA labeling via NIH DailyMed (set 053b9158…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.